Last reviewed 2026-05-16 · How we verify

Zavicefta, Ceftazidime-Avibactam (zavicefta-ceftazidime-avibactam)

Zavicefta, developed by Pfizer Inc., is a combination antibiotic that targets certain susceptible bacteria. It is used to treat complicated urinary tract infections, hospital-acquired bacterial pneumonia, and complicated intra-abdominal infections. Zavicefta's mechanism involves the combination of ceftazidime and avibactam, which work together to inhibit bacterial cell wall synthesis. This combination provides a unique clinical differentiation from other antibiotics. Zavicefta's commercial significance lies in its ability to treat resistant bacterial infections. The drug's pipeline developments are focused on expanding its indications and improving its efficacy.

At a glance

Approved indications

• Complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible bacteria.
• Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible bacteria.
• Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.

Common side effects

No common side effects on file.

Drug interactions

• Probencid
• Cyclosporine
• Methotrexate
• Aminoglycosides
• Penicillins
• Cephalosporins
• Monobactams
• Polymyxins
• Sulfonamides
• Chloramphenicol
• Tetracyclines
• Erythromycin

Key clinical trials

• A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
• A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
• A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
• Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (PHASE4)
• Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP) (PHASE4)
• Real-World Observational Study Of Zavicefta to Characterize Use Patterns

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Zavicefta, Ceftazidime-Avibactam CI brief — competitive landscape report
• Zavicefta, Ceftazidime-Avibactam updates RSS · CI watch RSS
• Pfizer portfolio CI